{
    "2021-11-30": [
        [
            {
                "time": "2021-11-30",
                "original_text": "恒瑞医药(SH600276)药品在SHR8058-301主要研究终点结果达到方案预设的优效标准",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR8058",
                        "临床试验",
                        "优效标准"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-30",
                "original_text": "恒瑞医药(SH600276)研发的SHR8058滴眼液治疗睑板腺功能障碍相关干眼病Ⅲ期临床试验(SHR8058-301)主要研究终点结果达到方案预设优效标准",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR8058",
                        "滴眼液",
                        "临床试验",
                        "优效标准"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-30",
                "original_text": "恒瑞医药(SH600276)：‘SHR-1909注射液’获药物临床试验批准通知书",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR-1909",
                        "注射液",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-30",
                "original_text": "恒瑞医药开展PD-L1单抗联合抗肿瘤活菌药物的全球临床研究有望为复发难治肿瘤患者带来新希望",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "PD-L1",
                        "单抗",
                        "抗肿瘤",
                        "临床研究"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-30",
                "original_text": "恒瑞医药收监管函！问询",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "监管函",
                        "问询"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-11-30",
                "original_text": "上交所向恒瑞医药下发监管函，微信群聊将试行打开电商类外链，抖音短剧或将开启付费模式",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "监管函",
                        "上交所",
                        "微信群聊",
                        "抖音短剧"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-11-30",
                "original_text": "3200亿医药巨头被监管，影响多大？",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "监管",
                        "医药巨头"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}